Abstract
Eleven schizophrenics (7 females) displaying an acute psychotic episode received the partial dopamine agonist terguride in doses up to 2 mg per day. Improvement in terms of positive symptoms reduction was observed in two cases only. In contrast, in a previous clinical trial targeted at negative schizophrenic symptoms, the majority of the patients appeared to have benefited from terguride application.
MeSH terms
-
Adolescent
-
Adult
-
Antipsychotic Agents / pharmacology
-
Antipsychotic Agents / therapeutic use*
-
Drug Evaluation
-
Female
-
Humans
-
Lisuride / analogs & derivatives*
-
Lisuride / pharmacology
-
Lisuride / therapeutic use
-
Psychological Tests
-
Receptors, Dopamine / drug effects
-
Receptors, Dopamine / physiology
-
Schizophrenia / drug therapy*
-
Schizophrenia / physiopathology
-
Schizophrenia, Paranoid / drug therapy
-
Schizophrenia, Paranoid / physiopathology
Substances
-
Antipsychotic Agents
-
Receptors, Dopamine
-
dironyl
-
Lisuride